filmov
tv
A Physiologically Based Pharmacokinetic Model to Predict the Superparamagnetic Iron Oxide...
Показать описание
A Physiologically Based Pharmacokinetic Model to Predict the Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Accumulation in Vivo
Speaker: Dr. Marco Siccardi, Lecturer, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool (UK)
"Routes Through the Body and the Cell: Pharmacokinetics and Intracellular Trafficking of Nanocarriers"
Chair - PD Dr. med. Volker Mailänder, Leader of the joint research group between the University Clinic Internal Medicine III, Johannes‐Gutenberg University Mainz and the Max Planck Institute (MPI) for Polymer Science, Mainz (D)
Day 3 Hall Rio
The European Summit for Clinical Nanomedicine and Targeted
Medicine – The Translation to Knowledge Based Medicine
Eighth Conference and Exhibition, June 28 – July 1, 2015
CLINAM 2015
1.7.2015
Speaker: Dr. Marco Siccardi, Lecturer, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool (UK)
"Routes Through the Body and the Cell: Pharmacokinetics and Intracellular Trafficking of Nanocarriers"
Chair - PD Dr. med. Volker Mailänder, Leader of the joint research group between the University Clinic Internal Medicine III, Johannes‐Gutenberg University Mainz and the Max Planck Institute (MPI) for Polymer Science, Mainz (D)
Day 3 Hall Rio
The European Summit for Clinical Nanomedicine and Targeted
Medicine – The Translation to Knowledge Based Medicine
Eighth Conference and Exhibition, June 28 – July 1, 2015
CLINAM 2015
1.7.2015
A Physiologically Based Pharmacokinetic Model to Predict the Superparamagnetic Iron Oxide...
A physiologically based pharmacokinetic (PBPK) model of pravastatin
PML School: Minimal Physiologically-based Pharmacokinetic Model for Monoclonal Antibodies (mAbs)
Physiologically based pharmacokinetic modeling for the simulation of relevant clinical scenarios
Physiologically-based Pharmacokinetics Modeling: An Approach for Designing Better Clinical Trials
First-In-Human (FIH) faster: The Power of Physiologically Based Pharmacokinetic (PBPK) Modeling
First-in-Human (FIH) Faster: The Power of Physiologically Based Pharmacokinetic Modeling - Recap
Application of Physiologically-based Pharmacokinetics (PBPK) to Personalized Dosing
Physiologically-based Pharmacokinetic Modeling (32of35) Complex Generics – Sep. 25-26, 2019
Physiologically Based Pharmacokinetic Modelling for First‑In‑Human Predictions
GastroPlus® Workshop: Physiologically Based Pharmacokinetic Modeling for FIH Predictions
Application of PBPK Modelling to Drug Development Decisions | Joga Gobburu, PhD, MBA
The Physiological Basis of Comparative Pharmacokinetics
ITB Meeting - Physiologically based pharmacokinetic (PBPK) models for liver function evaluation
A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development
FDA’s Perspective on Physiologically Based Pharmacokinetic Analyses for Biopharmaceutic Applications...
Physiologically Based Pharmacokinetic Model - In Urdu/Hindi
Common Myths about PBPK Modeling and Simulation- Busted!
Using PBPK Absorption Modeling to Support Biopharmaceutics Classification System Class 3 Drug Waiver
1 Introduction to PBPK Modeling
Physiology Based Pharmacokinetic Modeling in Generic Drug Development and Regulatory Decisions
Mastering Pharmacokinetics: What is Compartmental Modeling?
Pharmacokinetic Modeling of Air Lead and Blood Lead Level Relationship
Using PML to Perform Mechanistic Pharmacokinetic Modeling
Комментарии